Learn More
Invitrogen™ Dupilumab Recombinant Monoclonal Antibody

Recombinant Monoclonal Antibody
Brand: Invitrogen™ MA558671
Description
For reconstitution, add sterile, distilled water to achieve a final antibody concentration of 1 mg/mL. Gently shake to solubilize the protein completely. Do not vortex. Reconstituted products should be stored at -80 °.
Dupilumab with trade name Dupixent, is an FDA-approved drug for the treatment of patients aged 6 years and older with moderate-to-severe atopic dermatitis. It is a human monoclonal antibody. Dupilumab binds to the interleukin-4 receptor alpha (IL-4R alpha) subunit shared by the interleukin (IL)-4 and IL-13 receptor complexes, thereby inhibiting IL-4 and IL-13 signaling.
Specifications
| Dupilumab | |
| Recombinant Monoclonal | |
| Unconjugated | |
| Dupixent; REGN668; SAR231893 | |
| Protein A | |
| RUO | |
| Human | |
| Antibody | |
| IgG4SP |
| ELISA, Flow Cytometry, Functional Assay, Surface Plasmon Resonance | |
| 1 mg/mL | |
| 25mM histidine with 8% sucrose, 0.01% Tween 80 and no preservative; pH 6.2 | |
| Human | |
| 100 μg | |
| Primary | |
| -20°C, Avoid Freeze/Thaw Cycles | |
| Lyophilized |
Your input is important to us. Please complete this form to provide feedback related to the content on this product.